The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics
Open accessAbstract
Novel chemotherapeutics with marked and selective antitumor activity are essential to develop, particularly those that can overcome resistance to established therapies. Iron (Fe) is critical for cell-cycle progression and DNA synthesis and potentially represents a novel molecular target for the design of new anticancer agents. The aim of this study was to evaluate the antitumor activity and Fe chelation efficacy of a new class of Fe chelators using human tumors. In this investigation, the ligands showed broad antitumor activity and could overcome resistance to established antitumor agents. The in vivo efficacy of the most effective chelator identified, di-2-pyridylketone-4,4,-dimethyl-3-thiosemicarbazone (Dp44mT), was assessed by using a panel of human xenografts in nude mice. After 7 weeks, net growth of a melanoma xenograft in Dp44mT-treated mice was only 8% of that in mice treated with vehicle. In addition, no differences in these latter animals were found in hematological indices between Dp44mT-treated mice and controls. No marked systemic Fe depletion was observed comparing Dp44mT- and vehicle-treated mice, probably because of the very low doses required to induce anticancer activity. Dp44mT caused up-regulation of the Fe-responsive tumor growth and metastasis suppressor Ndrg1 in the tumor but not in the liver, indicating a potential mechanism of selective anticancer activity. These results indicate that the novel Fe chelators have potent and broad antitumor activity and can overcome resistance to established chemotherapeutics because of their unique mechanism of action.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chandel, N. S., McClintock, D. S., Feliciano, C. E., Wood, T. M., Melendez, J. A., Rodriguez, A. M., & Schumacker, P. T. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m001914200 · Cited by 2,000
Thelander, L., & Reichard, P. (1979) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.48.070179.001025 · Cited by 1,167
O'Connor, P. M., Jackman, J., Bae, I., Myers, T. G., Fan, S., Mutoh, M., Scudiero, D. A., Monks, A., Sausville, E. A., Weinstein, J. N., et al. (1997) · PubMed · Cited by 867
The Evolution of Iron Chelators for the Treatment of Iron Overload Disease and Cancer
Kalinowski, D. S., & Richardson, D. R. (2005) · Pharmacological Reviews · doi:10.1124/pr.57.4.2 · Cited by 721
Self-citationIsolation and genetic characterization of human KB cell lines resistant to multiple drugs
Akiyama, S.-I., Fojo, A., Hanover, J. A., Pastan, I., & Gottesman, M. M. (1985) · Somatic Cell and Molecular Genetics · doi:10.1007/bf01534700 · Cited by 529
Shen, D. W., Cardarelli, C., Hwang, J., Cornwell, M., Richert, N., Ishii, S., Pastan, I., & Gottesman, M. M. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)57466-x · Cited by 461
The role of iron in cell cycle progression and the proliferation of neoplastic cells
Le, N. (2002) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(02)00068-9 · Cited by 453
Richardson, D. R., Sharpe, P. C., Lovejoy, D. B., Senaratne, D., Kalinowski, D. S., Islam, M., & Bernhardt, P. V. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0606342 · Cited by 383
Self-citationYuan, J., Lovejoy, D. B., & Richardson, D. R. (2004) · Blood · doi:10.1182/blood-2004-03-0868 · Cited by 381
Self-citationFinch, R. A., Liu, M.-C., Grill, S. P., Rose, W. C., Loomis, R., Vasquez, K. M., Cheng, Y.-C., & Sartorelli, A. C. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(99)00419-0 · Cited by 366
Richardson, D., Tran, E., & Ponka, P. (1995) · Blood · doi:10.1182/blood.v86.11.4295.bloodjournal86114295 · Cited by 345
Self-citationLe, N. T. V., & Richardson, D. R. (2004) · Blood · doi:10.1182/blood-2004-05-1866 · Cited by 321
Self-citationThe Drg-1 gene suppresses tumor metastasis in prostate cancer.
Bandyopadhyay, S., Pai, S. K., Gross, S. C., Hirota, S., Hosobe, S., Miura, K., Saito, K., Commes, T., Hayashi, S., Watabe, M., et al. (2003) · PubMed · Cited by 308
Inhibition of tumor cell growth by RTP/rit42 and its responsiveness to p53 and DNA damage.
Kurdistani, S. K., Arizti, P., Reimer, C., Sugrue, M. M., Aaronson, S. A., & Lee, S. W. (1998) · PubMed · Cited by 278
Saad, S. Y., Najjar, T. A., & Al-Rikabi, A. C. (2001) · Pharmacological Research · doi:10.1006/phrs.2000.0769 · Cited by 259
Schneider, E., Horton, J. K., Yang, J. C., Nakagawa, M., & Cowan, K. H. (1994) · PubMed · Cited by 244
Molecular Pharmacology of the Interaction of Anthracyclines with Iron
Xu, X., Persson, H. L., & Richardson, D. R. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.013383 · Cited by 235
Self-citationGao, J., & Richardson, D. R. (2001) · Blood · doi:10.1182/blood.v98.3.842 · Cited by 224
Self-citationRichardson, D. R., & Milnes, K. (1997) · Blood · doi:10.1182/blood.v89.8.3025 · Cited by 205
Self-citationTP53: a key gene in human cancer
Guimaraes, D. P., & Hainaut, P. (2002) · Biochimie · doi:10.1016/s0300-9084(01)01356-6 · Cited by 203
Iron Chelators in Cancer Chemotherapy
Buss, J. L., Greene, B. T., Turner, J., Torti, F. M., & Torti, S. V. (2004) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026043387269 · Cited by 199
Lowe, S. W. (1995) · Current Opinion in ONCOLOGY · doi:10.1097/00001622-199511000-00013 · Cited by 194
(1979) · FEBS Letters · doi:10.1016/0014-5793(79)80111-8 · Cited by 190
Richardson, D. R., & Bernhardt, P. V. (1999) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s007750050312 · Cited by 144
Self-citationBrodie, C., Siriwardana, G., Lucas, J., Schleicher, R., Terada, N., Szepesi, Á., Gelfand, E. W., & Seligman, P. A. (1993) · PubMed · Cited by 132
Chaston, T. B., Watts, R., Yuan, J. J., & Richardson, D. R. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0865 · Cited by 129
Self-citationRichardson, D. R. (2005) · Current Medicinal Chemistry · doi:10.2174/092986705774462996 · Cited by 125
Self-citationPark, J.-H., Kim, T. Y., Jong, H.-S., Kim, T. Y., Chun, Y., Park, J., Lee, C., Jung, H. C., Kim, N. K., & Bang, Y. (2003) · PubMed · Cited by 123
The function of melanotransferrin: a role in melanoma cell proliferation and tumorigenesis
Dunn, L., Sekyere, E. O., Rahmanto, Y. S., & Richardson, D. R. (2006) · Carcinogenesis · doi:10.1093/carcin/bgl045 · Cited by 113
Self-citationBecker, E., Lovejoy, D. B., Greer, J. M., Watts, R., & Richardson, D. R. (2003) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705089 · Cited by 105
Self-citationBernhardt, P. V., Caldwell, L. M., Chaston, T. B., Chin, P., & Richardson, D. R. (2003) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-003-0486-z · Cited by 96
Self-citationYang, C.-H., Huang, C.-J., Yang, C.-S., Chu, Y.-C., Cheng, A., Whang‐Peng, J., & Yang, P. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0641 · Cited by 95
Hasinoff, B. B., Schnabl, K. L., Marusak, R. A., Patel, D., & Huebner, E. (2003) · Cardiovascular Toxicology · doi:10.1385/ct:3:2:89 · Cited by 91
Green, D. A., Antholine, W. E., Wong, S. J., Richardson, D. R., & Chitambar, C. R. (2001) · PubMed · Cited by 89
Self-citationp53-independent apoptosis mediated by tachpyridine, an anti-cancer iron chelator
Abeysinghe, R. D. (2001) · Carcinogenesis · doi:10.1093/carcin/22.10.1607 · Cited by 83
Immunosuppressors and reversion of multidrug-resistance
Aouali, N., Eddabra, L., Macadré, J., & Morjani, H. (2005) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2004.12.010 · Cited by 76
Balsari, A., Tortoreto, M., Besusso, D., Petrangolini, G., Sfondrini, L., Maggi, R., Ménard, S., & Pratesi, G. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.01.023 · Cited by 56
Chong, T. W., Horwitz, L. D., Moore, J. W., Sowter, H., & Harris, A. L. (2002) · PubMed · Cited by 38
A multifunctional cytoprotective agent that reduces neurodegeneration after ischemia
Jiang, Z.-G., Lu, X., Nelson, V. M., Yang, X., Pan, W., Chen, R., Lebowitz, M., Almassian, B., Tortella, F. C., Brady, R. O., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510573103 · Cited by 26
Iron chelation, angiogenesis and tumor therapy
Linden, T., & Wenger, R. H. (2003) · International Journal of Cancer · doi:10.1002/ijc.11223 · Cited by 12
Cited by
Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?
Trachootham, D., Alexandre, J., & Huang, P. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2803 · Cited by 5,452
“Other iron chelators that have been developed to alter ROS production are Dp44m”
BackgroundIron and cancer: more ore to be mined
Torti, S. V., & Torti, F. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3495 · Cited by 1,621
A review on anticancer potential of bioactive heterocycle quinoline
Afzal, O., Kumar, S., Haider, M. R., Ali, M. R., Kumar, R., Jaggi, M., & Bawa, S. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.07.044 · Cited by 798
Kell, D. B. (2009) · BMC Medical Genomics · doi:10.1186/1755-8794-2-2 · Cited by 554
Iron homeostasis and iron-regulated ROS in cell death, senescence and human diseases
Nakamura, T., Naguro, I., & Ichijo, H. (2019) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2019.06.010 · Cited by 523
Metadata
- Authors
- Whitnall, M., Howard, J., Ponka, P., & Richardson, D. R.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2006-10-03
- Volume
- 103
- Issue
- 40
- Pages
- 14901-14906
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W1977373583
- Cited by
- 509
- References
- 40
- FWCI
- 8.22
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.